Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $345

Benzinga Newsdesk www.benzinga.com Positive 89.9%

Neg 0% Neu 0% Pos 89.9%

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $342 to $345.